FDA-Approved Epilepsy Drug May Help Reverse Osteoarthritis Damage in Early Research

Osteoarthritis is a degenerative joint condition involving the gradual breakdown of cartilage, changes in underlying bone and inflammation-related processes that can contribute to pain and stiffness. Existing treatments can help manage symptoms, but options that reliably restore lost cartilage remain limited.

Researchers at Yale have investigated whether lacosamide, a medicine already approved for certain epilepsy treatments, could affect a protein involved in both pain signalling and cartilage damage. The early findings suggest that blocking this pathway may reduce damaging processes in the joint.

The research is significant because a medicine with an established clinical history may offer a useful starting point for investigating a different therapeutic application. However, safety and effectiveness for epilepsy do not automatically establish safety or effectiveness for osteoarthritis.

The reported findings are preliminary and should not be interpreted as evidence that patients can use lacosamide to regrow cartilage. Further studies are needed to evaluate dosage, safety, joint outcomes and whether the approach could benefit people with osteoarthritis.